@article{998bdd8573164a14b05bd1821844c8e5,
title = "Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2",
abstract = "Cerebral edema following chimeric antigen receptor (CAR) T-cell therapy can be fatal. ZUMA-2 is a pivotal phase 2, multicenter study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in relapsed/refractory mantle cell lymphoma. We describe a 65-year-old patient in ZUMA-2 who developed cerebral edema following CAR T-cell therapy and had complete recovery after multimodality clinical intervention including rabbit antithymocyte globulin (ATG). Biomarker results show early and robust CAR T-cell expansion and related induction of inflammatory cytokines, followed by rapid declines in CAR T-cell and proinflammatory cytokine levels after ATG administration. This clinical profile highlights a potential relevance of ATG in treating severe CAR T-cell-related neurotoxicity.",
keywords = "case reports, chimeric antigen",
author = "Michael Wang and Preetesh Jain and Chi, {T. Linda} and Chen, {Sheree E.} and Amy Heimberger and Weathers, {Shiao Pei} and Lianqing Zheng and Rao, {Arati V.} and Rossi, {John M.}",
note = "Funding Information: Acknowledgements We thank the staff at M.D. Anderson Cancer Center, including Maria Badillo, Javier A. Adachi, Imrana Malik, Luis E. Fayad, and Sudhakar Tummala; and Will Go of Kite, a Gilead Company, for patient management. Medical writing support was provided by Stephanie Morgan, PhD, (Nexus Global Group Science LLC) funded by Kite, A Gilead Company. Funding Information: This study was funded by Kite, A Gilead Company. Funding Information: Competing interests MW: honoraria from Pharmacyclics, Janssen, AstraZeneca, OMI, and Targeted Oncology; consultancy or advisory role for Pharmacyclics, Celgene, Janssen, AstraZeneca, MoreHealth, Pulse Biosciences, Nobel Insights, and Guidpoint Global; research funding from Pharmacyclics, Janssen, Novartis, Juno, Celgene, Loxo Oncology, VelosBio, and Verastem; expert testimony for AstraZeneca; and travel support from Janssen, Pharmacyclics, Celgene, and OMI. TLC: honoraria from Kite, a Gilead Company; consultancy or advisory role for Kite, a Gilead Company. AH: employment at M.D. Anderson; stock or other ownership in Caris; consultancy or advisory role for Caris and WCG Oncology; research funding from Merck; patents, royalties, or other intellectual property from Celldex. LZ and AVR: employment with Gilead Sciences. JMR: employment with Kite, A Gilead Company; stock or other ownership in Gilead Sciences.",
year = "2020",
month = oct,
day = "16",
doi = "10.1136/jitc-2020-001114",
language = "English (US)",
volume = "8",
journal = "Journal for immunotherapy of cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "2",
}